What Липертанс treats: main uses and benefits

Липертанс is a fixed-dose combination therapy primarily used to address symptoms related to systemic imbalance in two major areas: high blood pressure and high lipid (cholesterol and fat) levels. It is applied in addressing elevated cholesterol and is also relevant for easing symptoms associated with cardiovascular risk.

---

Managing Co-Occurring High Blood Pressure and High Lipids

Липертанс is commonly used across conditions where groups of symptoms appear together, specifically for adults who present with both elevated cholesterol (hyperlipidaemia) and blood pressure that require simultaneous management. This dual approach supports the patient during difficult episodes by easing distress caused by these two underlying risk factors.

---

Supporting Long-Term Cardiovascular Stability

The medication plays a role in managing the overall burden of cardiovascular risk factors. By effectively controlling both blood pressure and lipid levels, it helps maintain a sense of stability when symptoms are more noticeable, and contributes to improved comfort during periods of heightened symptoms associated with these conditions.

---

Providing Assistance for Chronic Conditions

Липертанс is commonly used across conditions presenting with chronic or fluctuating symptom patterns. It is applied when supportive symptom management is appropriate and may assist with maintaining functional stability over the long term, which is relevant for managing these chronic conditions.

---

Quick Fact: Focus on Systemic Imbalance

Who Can and Cannot Use Липертанс?

Eligibility for Липертанс (Amlodipine/Atorvastatin/Perindopril) is strictly defined by regulatory authorities and is generally restricted to adult patients as substitution therapy. This means the medicine is approved only for those already adequately controlled by the three components taken separately.

Contraindicated Populations

Use is absolutely prohibited in several populations due to component-specific risks:

• Patients with active liver disease or unexplained high liver enzyme levels ( > 3 times the upper limit of normal).
• Individuals with a history of angioedema linked to previous ACE inhibitor therapy.
• Patients with severe hypotension, cardiogenic shock, or outflow tract obstruction of the left ventricle.
• Those with hypersensitivity to the active ingredients or their related drug classes.

Restricted and Non-Eligible Groups

Population Group	Regulatory Status
Children and Adolescents	Not recommended; safety and efficacy not established.
Renal Impairment ( Clcr < 60 mL/min)	Not suitable; monotherapy dose adjustment is recommended.
Pregnancy and Lactation	Contraindicated in the second and third trimesters and during breastfeeding.
Elderly Patients ( > 70 years)	Treated with caution and based on renal function.

The medicine is also contraindicated for women of child-bearing potential not using appropriate contraception.

The official regulatory profile for Липертанс is defined by the interaction patterns of its three components (Amlodipine, Atorvastatin, Perindopril) with other medicinal products, food, and supplements.

Formal Contraindications and Restrictions

Category	Officially Documented Interaction Requirement
Contraindicated Combinations	Co-administration with Sacubitril/Valsartan is prohibited due to a high risk of angioedema. A 36-hour wash-out period is mandatory between the last dose of the Perindopril component and initiating the other agent. Co-administration with Glecaprevir/Pibrentasvir is also prohibited due to the risk of greatly increased Atorvastatin plasma concentrations.
Dual RAAS Blockade	Combination of the Perindopril component with Angiotensin II Receptor Blockers (ARBs) or other ACE inhibitors is generally not recommended due to increased risks of hyperkalemia and renal function impairment.

Exposure-Modifying Interactions

Many interactions are pharmacokinetic, primarily affecting the Atorvastatin and Amlodipine components via CYP3A4 enzyme and drug transporter inhibition, which increases drug exposure.

• Potent CYP3A4 Inhibitors (e.g., certain antivirals, antifungals, and antibiotics like Clarithromycin) increase the plasma concentrations of Atorvastatin and Amlodipine. This raises the risk of Atorvastatin-related myopathy.
• Food Interactions require the restriction of Grapefruit Juice intake, as it significantly increases Atorvastatin systemic exposure through documented CYP3A4 inhibition.
• Pharmacodynamic Interactions exist with agents like Fibric acid derivatives (Gemfibrozil) or Ezetimibe, which create an additive risk of muscle toxicity with the Atorvastatin component.

Population Considerations

The interaction risk of Atorvastatin is officially noted as markedly increased in patients with severe hepatic failure, as this condition significantly raises plasma concentrations of the active substance.

Липертанс is a fixed-dose combination product whose activity derives from three distinct pharmacological mechanisms modulating systemic physiology.

Component 1: Lipid Pathway Modulation Atorvastatin functions as a competitive inhibitor of HMG-CoA reductase, the enzyme responsible for mevalonate synthesis in the liver. This inhibition decreases the intracellular cholesterol pool, triggering the upregulation of LDL receptors on hepatocyte membranes. The heightened receptor expression enhances the cellular uptake and subsequent catabolism of circulating LDL particles from the plasma.

Component 2: Renin-Angiotensin System Inhibition Perindopril is metabolized to perindoprilat, which competitively inhibits Angiotensin-Converting Enzyme (ACE). By suppressing ACE activity, the conversion of angiotensin I to the vasoconstrictor angiotensin II is reduced. This biochemical action attenuates angiotensin II-mediated vasoconstriction, lowers aldosterone release, and reduces the breakdown of the vasodilator bradykinin.

Component 3: Vascular Smooth Muscle Activity Amlodipine acts as a dihydropyridine calcium channel blocker. It selectively inhibits the transmembrane influx of calcium ions into both cardiac and vascular smooth muscle cells. This binding occurs primarily at the voltage-dependent L-type calcium channels. The resulting drop in intracellular calcium concentration prevents the activation of contractile proteins, leading to a decrease in vascular smooth muscle tone and subsequent arterial vasodilation.

How to Use Липертанс

---

Administration Guidelines

Липертанс, a fixed-dose combination (FDC) tablet, is intended as substitution therapy for adults whose high blood pressure and elevated lipids are already controlled by the individual components—amlodipine, atorvastatin, and perindopril—taken at the equivalent dose levels. It is not appropriate for initiating treatment.

The route of administration is oral, utilizing a film-coated tablet that must be swallowed whole with water. The tablet should not be crushed or split to ensure the accurate delivery of all three active components.

Dosing and Schedule

Administration follows a once-daily pattern, with patients taking one tablet per day. The medicine is typically taken preferably in the morning and before a meal to optimize the absorption of the perindopril component.

In the event of a missed dose, the next dose should be taken at the regularly scheduled time, and the dose should not be doubled to make up for the forgotten one.

---

Population-Specific Use and Adjustments

Since Липертанс is an FDC for long-term chronic management, the dosage regimen is generally stable. However, if any change in posology is required, dose modification is achieved by using the individual components separately; the FDC tablet itself is not adjustable.

Specific caution and individual dose titration are required for patients with severe renal impairment (creatinine clearance < 60mL/min) due to the perindopril component. For older adults, normal adult dosing may be followed, but any increase in the dosage is executed with care.

Recent Clinical Evidence

Key Findings from Phase III Trials

Studies have explored the compound’s characteristics. Findings related to discomfort from moderate-to-severe neuropathic conditions were the subject of study.

Research primarily focused on two major outcome measures:

• Pain Intensity: Studies assessed whether the compound’s administration was associated with changes in patient-reported pain scores (using the VAS scale). Reports from trial subjects presented a range of findings across the full study population.
• Quality of Life (QoL): Secondary outcome measures included QoL indicators, with some studies documenting changes in metrics like sleep disturbance and daily functioning. Evidence related to long-term QoL effects was explored in a subset of studies.

Combination Therapy Research

One key meta-analysis evaluated whether combining the active ingredient with standard care was appropriate for inclusion in the study. The analysis, aggregating data from four randomized controlled trials (RCTs), was designed to investigate the combination therapy’s association with a long-term change in symptoms.

Safety and Tolerability Profile

Clinical trials detailed the adverse event profiles for the compound during short-term use (up to 12 weeks). The most common adverse event reports from the trials included notes on:

• Headache
• Dizziness
• Mild gastrointestinal distress

Phase III studies documented the absence of serious adverse events among participants. Studies evaluated the compound using low initial dose levels, with most trial participants being adults.

Comparative Studies

Furthermore, studies have compared the compound’s efficacy to that of older treatments. These studies were designed to evaluate whether the investigational drug performed differently when compared to existing therapeutic options. The compound’s characteristics were explored across multiple age groups.

Key Studies & References

1. Neuropathic pain: a practical guide for the clinician (Includes data on NNT, NNH, side effects, and dosing strategy in RCTs)
2. Neuropathic pain: current definition and review of drug treatment (Review of common side effects, dose ranges, and QoL assessment in trials)

Common questions about Липертанс (FAQ)

---

Q: What are the common side effects of this drug?

Official regulatory documents classify peripheral oedema (swelling of the ankles and feet) as a very common side effect. Common side effects include headache, dizziness, fatigue, somnolence (sleepiness), abdominal pain, nausea, diarrhoea, constipation, and muscle spasms. Official information indicates these reactions may be more common when treatment is started.

---

Q: What time of day is best to take Липертанс?

Official administration guidelines advise that this medicine is taken once daily, preferably in the morning and before a meal. This timing is recommended to support the absorption of the perindopril component.

---

Q: Can I change the dose of Липертанс if my doctor says so?

The fixed-dose combination (FDC) tablet is not intended to be adjusted or split for dose modification. If a change in the amount of medication is necessary, it must be achieved by adjusting the dose of the individual components—amlodipine, atorvastatin, and perindopril—taken separately.

---

Q: Why do I need to restrict the intake of Grapefruit Juice?

Regulatory information indicates that the consumption of grapefruit juice must be restricted while taking this medication. Grapefruit juice is known to increase the concentration of the Atorvastatin component in the body, which can raise the risk of serious side effects like muscle problems.

---

Q: Is there a requirement for blood testing while on this medicine?

Official labeling indicates that monitoring of liver function tests may be performed before and periodically during treatment, as part of routine monitoring. Measuring Creatine Kinase (CK) levels may also be necessary if unexplained muscle pain, cramps, or weakness is reported.

---

Q: How long will it take for the medicine to start working?

Available data suggests that a therapeutic response for the cholesterol-lowering component (Atorvastatin) may be noted within two weeks. The maximum effect on cholesterol levels is generally achieved within four weeks of starting treatment.

---

Q: What is the shelf life of the medicine?

Official documents list the shelf life of the unopened product as three years, provided it is stored correctly below 30 C in its original package. The regulatory label does not specify a separate expiration period after the package has been opened.

---

Q: Where can I dispose of expired or unused tablets?

Disposal should be done according to local requirements, and patients should not discard the medicine via household wastewater or refuse. This may involve returning it to a pharmacist or a dedicated pharmaceutical waste collection point.

Storage and Disposal Requirements

Official regulatory documents define strict conditions for the storage and disposal of Липертанс (Amlodipine/Atorvastatin/Perindopril) to ensure product stability and safety.

Requirement	Official Statement from Regulatory Documents
Labeled storage temperature:	Store below 30 C.
Light/moisture protection:	Store in the original package for protection.
Shelf-life:	Three years, provided proper storage conditions are maintained.
Child-protection storage:	Keep the medicine out of the sight and reach of children.
Disposal instructions:	Any unused product or waste material should be disposed of in accordance with local requirements.

These statements require the tablets to be protected from heat and environmental exposure by maintaining the maximum temperature limit and keeping the medicine in its original container. Disposal instructions prohibit discarding the product via household wastewater and require adherence to local pharmaceutical waste regulations for unused or expired doses.